Targeting MET in cancer: rationale and progress
- PMID: 22270953
- DOI: 10.1038/nrc3205
Targeting MET in cancer: rationale and progress
Erratum in
- Nat Rev Cancer. 2012 Sep;12(9):637
Abstract
Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of cancer. Genetic and biochemical data have demonstrated that the growth and motility factor hepatocyte growth factor/scatter factor (HGF/SF) and its receptor, the tyrosine kinase MET, have a causal role in all of these processes, thus providing a strong rationale for targeting these molecules in cancer. Parallel progress in understanding the structure and function of HGF/SF, MET and associated signalling components has led to the successful development of blocking antibodies and a large number of small-molecule MET kinase inhibitors. In this Review, we discuss these advances, as well as results from recent clinical studies that demonstrate that inhibiting MET signalling in several types of solid human tumours has major therapeutic value.
Similar articles
-
Signalling by HGF/SF and Met: the role of heparan sulphate co-receptors.Biochem Soc Trans. 2006 Jun;34(Pt 3):414-7. doi: 10.1042/BST0340414. Biochem Soc Trans. 2006. PMID: 16709175 Review.
-
Expression of hepatocyte growth factor/scatter factor and its receptor c-Met in brain tumors: evidence for a role in progression of astrocytic tumors (Review).Int J Mol Med. 1999 May;3(5):531-6. doi: 10.3892/ijmm.3.5.531. Int J Mol Med. 1999. PMID: 10202187 Review.
-
A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.Clin Cancer Res. 2008 Jul 15;14(14):4612-21. doi: 10.1158/1078-0432.CCR-08-0108. Clin Cancer Res. 2008. PMID: 18628476
-
Gene of the month: MET.J Clin Pathol. 2015 Jun;68(6):405-9. doi: 10.1136/jclinpath-2015-203050. Epub 2015 Apr 22. J Clin Pathol. 2015. PMID: 25987653 Review.
-
Hepatocyte growth factor/MET in cancer progression and biomarker discovery.Cancer Sci. 2017 Mar;108(3):296-307. doi: 10.1111/cas.13156. Cancer Sci. 2017. PMID: 28064454 Free PMC article. Review.
Cited by
-
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.BMC Cancer. 2021 Feb 26;21(1):200. doi: 10.1186/s12885-020-07722-3. BMC Cancer. 2021. PMID: 33637083 Free PMC article.
-
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme.J Mol Med (Berl). 2013 Apr;91(4):439-48. doi: 10.1007/s00109-013-1019-z. Epub 2013 Mar 20. J Mol Med (Berl). 2013. PMID: 23512266 Free PMC article. Review.
-
High c-Met expression is a negative prognostic marker for colorectal cancer: a meta-analysis.Tumour Biol. 2015 Feb;36(2):515-20. doi: 10.1007/s13277-014-2659-5. Epub 2015 Jan 31. Tumour Biol. 2015. PMID: 25636446 Review.
-
The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.J Biol Chem. 2016 Sep 30;291(40):20891-20899. doi: 10.1074/jbc.M116.727875. Epub 2016 Aug 18. J Biol Chem. 2016. PMID: 27539855 Free PMC article.
-
PKG II reverses HGF-triggered cellular activities by phosphorylating serine 985 of c-Met in gastric cancer cells.Oncotarget. 2016 Jun 7;7(23):34190-200. doi: 10.18632/oncotarget.9074. Oncotarget. 2016. PMID: 27147579 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous